Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Pradaxa

- PMLiVE

Boehringer eyes obesity market

Aims to widen metabolism portfolio beyond diabetes

Bayer symbol

Bayer moves closer to US approval of PAH drug riociguat

FDA panel votes unanimously in favour of hypertension treatment

- PMLiVE

FDA panel turns down Otsuka’s drug for rare kidney disease

Unable to recommend expanded use of tolvaptan

- PMLiVE

GSK’s diabetes hope albiglutide delayed in US

FDA extends deadline to April 2014

Sanofi reception

FDA panel backs OTC use of Sanofi’s allergy drug

Says Nasacort AQ can be sold without prescription

- PMLiVE

Boehringer: clinical trial set-up poses challenge in rare diseases

Says more support needed in regulatory process for orphan drugs

Actelion HQ Switzerland

Actelion to buy Ceptaris – if FDA backs its cancer treatment

Acquisition contingent on Valchlor approval in rare lymphoma

FDA grants priority review to pain drug

Mallinckrodt’s MNK-795 is intended for the management of moderate to severe acute pain

- PMLiVE

Boehringer’s first cancer drug leads EMA recommendations

Afatinib recommended for lung cancer under brand name Giotrif

- PMLiVE

AZ and BMS try again with Forxiga in the US

Pharma companies re-submit diabetes drug to the FDA for approval

- PMLiVE

FDA panel fails to back new use for AbbVie’s Humira

Votes 12 to 1 against new use in spondyloarthritis

Biogen Idec building

Biogen Idec’s long-acting beta interferon moves ahead in MS

US and EU accept filings for long-acting multiple sclerosis drug Plegridy

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links